Suchergebnisse - "Laterre, Pierre-François"

PubPharm (15)

1

The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia : A randomized clinical trial

enthalten in: Journal of critical care | 2024

von Laterre, P. | Sánchez García, M. | van der Poll, T. | +12

2

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH) : a double-blind, randomised, controlled, phase 2b trial

enthalten in: The Lancet. Respiratory medicine | 2023

von François, B. | Lambden, S. | Fivez, T. | +50

CommentIn: Lancet Respir Med. 2023 Oct;11(10):855-857. - PMID 37269869

3

Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE Study

enthalten in: Journal of clinical microbiology | 2022

von Ruzin, A. | Barraud, O. | Yu, L. | +26

4

Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients : the AdrenOSS-2 phase 2a biomarker-guided trial

enthalten in: Intensive care medicine | 2021

von Laterre, P. | Pickkers, P. | Marx, G. | +77

5

Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE) : a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial

enthalten in: The Lancet. Infectious diseases | 2021

von François, B. | Jafri, H. | Chastre, J. | +104

CommentIn: Lancet Infect Dis. 2021 Sep;21(9):1201-1202. - PMID 33894132

6

Nangibotide in patients with septic shock : a Phase 2a randomized controlled clinical trial

enthalten in: Intensive care medicine | 2020

von François, B. | Wittebole, X. | Ferrer, R. | +13

7

Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus : first-in-human trial

enthalten in: Intensive care medicine | 2018

von François, B. | Mercier, E. | Gonzalez, C. | +66

8

Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury : A Randomized Clinical Trial

enthalten in: JAMA | 2018

von Pickkers, P. | Mehta, R. | Murray, P. | +119

CommentIn: Anaesth Crit Care Pain Med. 2019 Feb;38(1):1-2. - PMID 30635097

9

Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial

enthalten in: Annals of the American Thoracic Society | 2018

von Lewis, R. | Angus, D. | Laterre, P. | +14

10

Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

enthalten in: Critical care (London, England) | 2017

von Russell, J. | Vincent, J. | Kjølbye, A. | +6